A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation protects at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can vary from causing mild, cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine functions by stimulating the mother’s immune system to generate protective antibodies, which are then transferred to the foetus through the placenta. This mother-derived protection offers newborns with immediate protection from the moment of birth, precisely when they are most vulnerable to RSV. The new study shows that protection reaches nearly 85 per cent when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence suggesting that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to receive the vaccine at the recommended time, whilst observing that protection can still occur even if administered later in the third trimester.
- Nearly 85 per cent coverage when vaccinated four weeks before birth
- Antibodies from the mother passed through placenta protect newborns from day one
- Protection possible with two-week gap before early delivery
- Vaccination in the third trimester still offers significant protection for infants
Strong evidence from current research
The performance of the pregnancy RSV vaccine has been confirmed through a extensive research programme carried out throughout England, analysing data from nearly 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90% of all births during that six-month period, providing comprehensive and reliable data of the vaccine’s practical effectiveness. The study’s results have been supported by the UK Health Security Agency as showing strong protection for newborns during their most critical early weeks. The scale of this research gives healthcare professionals and parents-to-be with assurance in the vaccine’s proven efficacy across different groups and contexts.
The results reveal a notable picture of the vaccine’s protective effectiveness. More than 4,500 babies were hospitalised with RSV during the study period, with the vast majority being infants whose mothers did not receive the vaccination. This clear distinction highlights the vaccine’s critical role in protecting against serious illness in newborns. The decrease in hospital admissions exceeding 80 per cent represents a substantial public health milestone, potentially preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms associated with severe RSV infection. These findings reinforce the importance of the vaccination programme introduced in the UK in 2024.
Study methodology and scope
The research examined birth and hospital admission records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection rates and hospital admissions. The substantial sample size and thorough nature of the data gathering ensured that findings were statistically robust and representative of the broader population, rather than individual cases or limited subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to establish the least amount of time between vaccination and birth for optimal protection, as well as to determine whether protection continued to be effective with briefer timeframes. The methodology measured actual clinical results rather than controlled laboratory conditions, providing tangible evidence of how the vaccine functions when delivered across different clinical contexts and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and its dangers
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.
The infection causes deep inflammation in the lungs and airways, making it extremely challenging for vulnerable newborns to feed and breathe adequately. Parents often witness their babies struggling visibly, their chests heaving as they work to get sufficient oxygen into their damaged lungs. Whilst the majority of babies get better with palliative treatment, a limited though important group succumb from respiratory syncytial virus complications yearly, making prevention through vaccination a vital health service priority for protecting the youngest and most at-risk members of society.
- RSV triggers inflammation in lungs, causing serious respiratory problems in babies
- Half of all newborns acquire the infection during their first few months alive
- Symptoms span from mild colds to life-threatening chest infections needing hospital treatment
- Over 20,000 UK infants need serious hospital treatment for RSV annually
- A small number of babies die from RSV related complications each year in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme began in 2024, health officials have stressed the importance of pregnant women receiving their jab at the optimal time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that timing is crucial for guaranteeing newborns benefit from the most robust immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery offers nearly 85% protection, experts recommend women to get their vaccine as early as possible from 28 weeks of pregnancy forward to increase the antibodies passed to their babies through the placenta.
The guidance from health authorities stays clear: pregnant women should make a priority of vaccination during their final three months, even if circumstances mean they cannot receive the jab at the best timing. Dr Watson has provided reassurance to pregnant women that protection remains still achievable with shorter intervals between vaccination and birth, including even a fourteen-day window for those delivering slightly early. This adaptable strategy acknowledges the realities of pregnancy and childbirth whilst ensuring strong safeguarding for vulnerable newborns during their most critical early months when RSV represents the highest danger of serious illness.
Regional differences in vaccine uptake
Whilst the RSV vaccine programme has been launched across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Certain regions have achieved greater immunisation rates among qualifying expectant mothers, whilst others remain focused to boost understanding and availability of the jab. These geographical variations demonstrate differences across medical facilities, engagement approaches, and local engagement efforts, though the national data shows robust and reliable protection irrespective of geographical location.
- NHS trusts launching multiple messaging strategies to reach women during pregnancy
- Regional disparities in immunisation take-up across England demand focused enhancement
- Local healthcare systems modifying schemes to align with community needs and circumstances
Real-world impact and parental perspectives
The vaccine’s remarkable effectiveness delivers tangible benefits for families throughout the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV before the introduction of this preventative solution, the 80% decrease in admissions equates to thousands of infants spared from severe infection. Parents no longer face the upsetting situation of seeing their babies struggle for breath or difficulty feeding, symptoms that define serious RSV disease. The vaccine has substantially transformed the picture of neonatal respiratory health, offering expectant mothers a active means to protect their youngest infants during those vital initial period.
For families like that of Malachi, whose severe RSV infection resulted in severe brain damage, the vaccine’s availability carries profound emotional significance. His mother’s advocacy for the jab emphasises the profound consequences that vaccine-preventable disease can cause to young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story strikes a chord with parents now provided with protection. The knowledge that such grave complications—hospital stay, oxygen dependency, neurological damage—are now largely avoidable has offered substantial reassurance to expectant mothers in their late pregnancy, changing what was once an unavoidable seasonal threat into a controllable health concern.